Skip to main content

31-05-2020 | ASCO 2020 | Conference coverage | Video

Expert comment: Antiandrogens in nonmetastatic CRPC

Tomasz Beer highlights the key messages and caveats of the overall survival data from the PROSPER, SPARTAN, and ARAMIS trials of enzalutamide, apalutamide, and darolutamide, respectively, in the nonmetastatic castration-resistant prostate cancer setting (10:25).

Read transcript

Have your say on Medicine Matters

Visit the conference hub

Image Credits